{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:58:01Z","timestamp":1785787081861,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004470","name":"Daewoong Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004470","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"DOI":"10.1007\/s00198-026-08172-6","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:47:43Z","timestamp":1785739663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Smartphone-based patient-reported outcome of acute phase reaction after zoledronic acid infusion and prediction algorithm: a multicenter, prospective cohort study"],"prefix":"10.1007","author":[{"given":"Sung Joon","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Wouk","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Heui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng Chan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Hee","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumie","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8246-1956","authenticated-orcid":false,"given":"Namki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"18","key":"8172_CR1","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa067312","journal-title":"N Engl J Med"},{"issue":"12","key":"8172_CR2","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman Dijkstra NM, Makras P (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2 year clinical trial. J Bone Miner Res 34(12):2220\u20132228. https:\/\/doi.org\/10.1002\/jbmr.3853","journal-title":"J Bone Miner Res"},{"issue":"9","key":"8172_CR3","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95(9):4380\u20134387. https:\/\/doi.org\/10.1210\/jc.2010-0597","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"8172_CR4","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.bone.2012.02.006","volume":"50","author":"AD Anastasilakis","year":"2012","unstructured":"Anastasilakis AD, Polyzos SA, Makras P et al (2012) Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. Bone 50(5):1130\u20131134. https:\/\/doi.org\/10.1016\/j.bone.2012.02.006","journal-title":"Bone"},{"issue":"1","key":"8172_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-017-0316-5","volume":"12","author":"E Durden","year":"2017","unstructured":"Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R (2017) Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos 12(1):22. https:\/\/doi.org\/10.1007\/s11657-017-0316-5","journal-title":"Arch Osteoporos"},{"issue":"10","key":"8172_CR6","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s00198-016-3623-6","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, Kyvernitakis I, Kann PH et al (2016) GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int 27(10):2967\u20132978. https:\/\/doi.org\/10.1007\/s00198-016-3623-6","journal-title":"Osteoporos Int"},{"issue":"6","key":"8172_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00198-006-0294-8","volume":"18","author":"E Seeman","year":"2007","unstructured":"Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, J\u00f6nsson B, Pols H, Cramer JA (2007) Non-compliance: the Achilles\u2019 heel of anti-fracture efficacy. Osteoporos Int 18(6):711\u2013719. https:\/\/doi.org\/10.1007\/s00198-006-0294-8","journal-title":"Osteoporos Int"},{"issue":"8","key":"8172_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013\u20131022. https:\/\/doi.org\/10.4065\/81.8.1013","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"8172_CR9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3803\/EnM.2024.2252","volume":"40","author":"KJ Kim","year":"2025","unstructured":"Kim KJ, Boo D, Choi J, Yoon H, Jung CY, Ahn SH, Hong N, Kim BJ, Oh JS, You SC (2025) Comprehensive evaluation of treatment patterns in postmenopausal patients with osteoporosis without fractures: insights from tertiary care institutions and nationwide OMOP-CDM data. Endocrinol Metab (Seoul) 40(5):737\u2013747. https:\/\/doi.org\/10.3803\/EnM.2024.2252","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"5","key":"8172_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/jbmr.4802","volume":"38","author":"R Murdoch","year":"2023","unstructured":"Murdoch R, Mellar A, Horne AM, Billington E, Chan PL, Gamble GD, Reid IR (2023) Effect of a three-day course of dexamethasone on acute phase response following treatment with zoledronate: a randomized controlled trial. J Bone Miner Res 38(5):631\u2013638. https:\/\/doi.org\/10.1002\/jbmr.4802","journal-title":"J Bone Miner Res"},{"issue":"5","key":"8172_CR11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jama.2022.11238","volume":"328","author":"KP Weinfurt","year":"2022","unstructured":"Weinfurt KP, Reeve BB (2022) Patient-reported outcome measures in clinical research. JAMA 328(5):472\u2013473. https:\/\/doi.org\/10.1001\/jama.2022.11238","journal-title":"JAMA"},{"key":"8172_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-0305-8","volume":"3","author":"KI Taylor","year":"2020","unstructured":"Taylor KI, Staunton H, Lipsmeier F, Nobbs D, Lindemann M (2020) Outcome measures based on digital health technology sensor data: data- and patient-centric approaches. npj Digit Med 3:97. https:\/\/doi.org\/10.1038\/s41746-020-0305-8","journal-title":"npj Digit Med"},{"issue":"22","key":"8172_CR13","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1056\/NEJMe2303219","volume":"389","author":"SH Friend","year":"2023","unstructured":"Friend SH, Ginsburg GS, Picard RW (2023) Wearable digital health technology. N Engl J Med 389(22):2100\u20132101. https:\/\/doi.org\/10.1056\/NEJMe2303219","journal-title":"N Engl J Med"},{"issue":"3","key":"8172_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1359\/jbmr.090819","volume":"25","author":"F Bertoldo","year":"2010","unstructured":"Bertoldo F, Pancheri S, Zenari S, Boldini S, Giovanazzi B, Zanatta M, Valenti MT, Dalle Carbonare L, Lo Cascio V (2010) Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res 25(3):447\u2013454. https:\/\/doi.org\/10.1359\/jbmr.090819","journal-title":"J Bone Miner Res"},{"issue":"6","key":"8172_CR15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s00223-021-00884-7","volume":"109","author":"M Shiraki","year":"2021","unstructured":"Shiraki M, Kuroda T, Takeuchi Y, Sugimoto T, Tanaka S, Suzuki H, Hiraishi K, Nakamura T (2021) Acute phase reactions after intravenous infusion of zoledronic acid in Japanese patients with osteoporosis: sub-analyses of the phase III ZONE study. Calcif Tissue Int 109(6):666\u2013674. https:\/\/doi.org\/10.1007\/s00223-021-00884-7","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"8172_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4158\/ep161638.Or","volume":"24","author":"C Crotti","year":"2018","unstructured":"Crotti C, Watts NB, De Santis M, Ceribelli A, Fabbriciani G, Cavaciocchi F, Marasini B, Selmi C, Massarotti M (2018) Acute phase reactions after zoledronic acid infusion: protective role of 25-hydroxy vitamin D and previous oral bisphosphonate therapy. Endocr Pract 24(5):405\u2013410. https:\/\/doi.org\/10.4158\/ep161638.Or","journal-title":"Endocr Pract"},{"issue":"2","key":"8172_CR17","first-page":"103","volume":"17","author":"YKBJ Lee","year":"2010","unstructured":"Lee YKBJ, Ha YC, Koo KH (2010) Predictors of acute phase response after intravenous zoledronic acid in patients with osteoporotic fracture. Korean J Bone Metab 17(2):103\u2013107","journal-title":"Korean J Bone Metab"},{"issue":"1","key":"8172_CR18","first-page":"49","volume":"18","author":"SHCH Seo","year":"2011","unstructured":"Seo SHCH, Cheon SH, Jeong HM, Park IH (2011) Could prior oral-bisphosphonate administration reduce the acute phase reaction of zoledronate? Korean J Bone Metab 18(1):49\u201354","journal-title":"Korean J Bone Metab"},{"issue":"3","key":"8172_CR19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837\u2013845","journal-title":"Biometrics"},{"issue":"9","key":"8172_CR20","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1001\/jama.271.9.703","volume":"271","author":"R Jaeschke","year":"1994","unstructured":"Jaeschke R, Guyatt GH, Sackett DL (1994) Users\u2019 guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 271(9):703\u2013707. https:\/\/doi.org\/10.1001\/jama.271.9.703","journal-title":"JAMA"},{"issue":"4","key":"8172_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00198-020-05653-0","volume":"32","author":"FP Chen","year":"2021","unstructured":"Chen FP, Fu TS, Lin YC, Lin YJ (2021) Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion. Osteoporos Int 32(4):663\u2013670. https:\/\/doi.org\/10.1007\/s00198-020-05653-0","journal-title":"Osteoporos Int"},{"issue":"2","key":"8172_CR22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00774-019-01050-8","volume":"38","author":"N Okimoto","year":"2020","unstructured":"Okimoto N, Sakai A, Yoshioka T et al (2020) Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study. J Bone Miner Metab 38(2):230\u2013239. https:\/\/doi.org\/10.1007\/s00774-019-01050-8","journal-title":"J Bone Miner Metab"},{"issue":"8","key":"8172_CR23","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00198-010-1448-2","volume":"22","author":"SL Silverman","year":"2011","unstructured":"Silverman SL, Kriegman A, Goncalves J, Kianifard F, Carlson T, Leary E (2011) Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporos Int 22(8):2337\u20132345. https:\/\/doi.org\/10.1007\/s00198-010-1448-2","journal-title":"Osteoporos Int"},{"issue":"2","key":"8172_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1740774511430516","volume":"9","author":"S Greenspan","year":"2012","unstructured":"Greenspan S, Nace D, Perera S et al (2012) Lessons learned from an osteoporosis clinical trial in frail long-term care residents. Clin Trials 9(2):247\u2013256. https:\/\/doi.org\/10.1177\/1740774511430516","journal-title":"Clin Trials"},{"issue":"6","key":"8172_CR25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamainternmed.2015.0747","volume":"175","author":"SL Greenspan","year":"2015","unstructured":"Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM (2015) Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med 175(6):913\u2013921. https:\/\/doi.org\/10.1001\/jamainternmed.2015.0747","journal-title":"JAMA Intern Med"},{"issue":"18","key":"8172_CR26","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa2028982","volume":"384","author":"TB Corcoran","year":"2021","unstructured":"Corcoran TB, Myles PS, Forbes AB et al (2021) Dexamethasone and surgical-site infection. N Engl J Med 384(18):1731\u20131741. https:\/\/doi.org\/10.1056\/NEJMoa2028982","journal-title":"N Engl J Med"},{"issue":"4","key":"8172_CR27","doi-asserted-by":"publisher","first-page":"xv","DOI":"10.1016\/j.ecl.2022.06.001","volume":"51","author":"EB Geer","year":"2022","unstructured":"Geer EB (2022) Patient-reported outcomes in endocrinology. Endocrinol Metab Clin North Am 51(4):xv\u2013xvi. https:\/\/doi.org\/10.1016\/j.ecl.2022.06.001","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"8","key":"8172_CR28","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jama.2013.879","volume":"309","author":"M Calvert","year":"2013","unstructured":"Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309(8):814\u2013822. https:\/\/doi.org\/10.1001\/jama.2013.879","journal-title":"JAMA"},{"key":"8172_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211015958","volume":"12","author":"OL Aiyegbusi","year":"2021","unstructured":"Aiyegbusi OL, Nair D, Peipert JD, Schick-Makaroff K, Mucsi I (2021) A narrative review of current evidence supporting the implementation of electronic patient-reported outcome measures in the management of chronic diseases. Ther Adv Chronic Dis 12:20406223211015958. https:\/\/doi.org\/10.1177\/20406223211015958","journal-title":"Ther Adv Chronic Dis"},{"issue":"3","key":"8172_CR30","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41591-024-02827-9","volume":"30","author":"OL Aiyegbusi","year":"2024","unstructured":"Aiyegbusi OL, Cruz Rivera S, Roydhouse J et al (2024) Recommendations to address respondent burden associated with patient-reported outcome assessment. Nat Med 30(3):650\u2013659. https:\/\/doi.org\/10.1038\/s41591-024-02827-9","journal-title":"Nat Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08172-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08172-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08172-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:03:19Z","timestamp":1785783799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-08172-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":30,"alternative-id":["8172"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08172-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study protocol was approved by the Institutional Review Board (IRB) of Severance Hospital (IRB No. 4-2021-1723) and by the IRB of all participating institutions. Written informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Outside the submitted work, Seng Chan You reports grants from Daiichi Sankyo. Seng Chan You receives compensation as an Associate Editor for JACC. Dr. You is a Chief Executive Officer of PHI Digital Healthcare. Yumie Rhee has received honorarium from Amgen. Yumie Rhee has been an investigator for Amgen, Kyowa Kirin, Hanmi, Dongook, Donaga ST, and Daewoong. Sung Joon Cho, Sang Wouk Cho, Min Heui Yu, Seong Hee Ahn, and Namki Hong declare that they have no conflict of interest.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}